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The Maternal and Child Health Bureau commissioned the American College of Medical Genetics to outline a
process for the standardization of outcomes and guidelines for state newborn screening programs and to define
responsibilities for collecting and evaluating outcome data, including a recommended uniform panel of conditions
to include in state newborn screening programs. The expert panel identified 29 conditions for which screening
should be mandated. An additional 25 conditions were identified because they are part of the differential diagnosis
of a condition in the core panel, they are clinically significant and revealed with screening technology but lack an
efficacious treatment, or they represent incidental findings for which there is potential clinical significance. The
process of identification is described, and recommendations are provided. Genet Med 2006:8(5, Supplement):
1S–11S.
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INTRODUCTION
In the United States, newborn screening is a highly visible
and important state-based public health program that began
over 40 years ago. States and territories mandate newborn
screening of all infants born within their jurisdiction for
certain disorders that may not otherwise be detected before
developmentaldisabilityordeathoccurs.Newbornswiththese
disorders typically appear normal at birth. Appropriate com-
pliance with the medical management prescribed can allow
mostaffectednewbornstodevelopnormally.Asthemodelfor
public health-based population genetic screening, newborn
screening is nationally recognized as an essential program that
aimstoensurethebestoutcomeforthenation’snewbornpop-
ulation.
AsidefromtheNationalCommitteeforClinicalLaboratory
Standards (NCCLS) “Standard on Blood Collection on Filter
Paper” and guidance from the Council of Regional Networks
for Genetic Services (CORN), funded by the Health Resources
and Services Administration (HRSA), there are no national
newborn screening standards, and limited advice is available
from national advisory committees and national medical or
public health professional organizations regarding newborn
screening policies and conditions to be included in screening
mandates. The level of state resources available (personnel,
equipment, service capacity); the programs’ interpretations of
available evidence concerning given conditions (incidence,
treatability, impact); the availability or expense of new screen-
ing methodologies; or public advocacy by families, health care
professionals or state legislators have often led to divergence
among states regarding which conditions should be mandated
for newborn screening. This divergence has resulted in signif-
icant disparities in screening services available to infants. In-
deed, in 1999, the American Academy of Pediatrics (AAP)
Newborn Screening Task Force indicated that greater unifor-
mity among programs would benefit families, professionals,
and public health agencies.
The public health system faces many challenges as newborn
screening capabilities continue to evolve. The health care ser-
vice infrastructure is limited with regard to the interconnec-
tions among primary care professionals and subspecialists,
particularlyinruralareas,aproblemcomplicatedbythenum-
beranddiversityofveryrareconditionsidentifiedinnewborn
screening programs. There are geographic limitations in the
availability of specific expertise for many of the rare condi-
tions, and considerable needs exist in the areas of training and
education about the disorders detected through newborn
screening programs throughout the health care system. Fur-
thermore,improvementsinthenewbornscreeningsystemand
theexpansionofthenumberofconditionsforwhichscreening
isofferedhavecosts,andthesecostsandtheassociatedbenefits
seem to accrue independently of the public and private health
care delivery systems, which complicates their integration.
Many states provide the programs necessary to ensure that
screeninganddiagnosiswilloccur,buttheyarelimitedintheir
ability to ensure long-term management, including the provi-
sion of the necessary treatment and services.
In addition, new technologies have brought three major
challenges to newborn screening: 1) expanding knowledge
base of the etiology and therefore the treatment or potential
treatment of genetic diseases; 2) rapid expansion of diverse
technologies such as multiplex platforms that may be used in
screening; 3) increased use of tiered testing strategies to en-
hance the positive predictive value of an initial abnormal re-
sult. The lack of newborn screening program uniformity for
infants, the changing dynamics of emerging technology, and
thecomplexityofgeneticsrequireanassessmentofthestateof
the art in newborn screening and a perspective on the future
directions such programs could take. In 1999, the AAP New-
born Screening Task Force recommended that “HRSA should
engage in a national process involving government, profes-
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this Task Force and assist in the development and implemen-
tation of nationally recognized newborn screening system
standards and policies.”
In response to this need, the Maternal and Child Health
Bureau (MCHB) of HRSA commissioned the American Col-
lege of Medical Genetics (ACMG) to outline a process of stan-
dardization of outcomes and guidelines for state newborn
screeningprogramsandtodefineresponsibilitiesforcollecting
and evaluating outcome data, including a recommended uni-
formpanelofconditionstoincludeinstatenewbornscreening
programs. It was expected that the analytical endeavor and
subsequentrecommendationswouldbedefinitiveandthatthe
subsequent recommendations be based on the best scientific
evidence and analysis of that evidence. ACMG was specifically
asked to develop recommendations to address:
1. A uniform condition panel (including implementation
methodology);
2. Modelpoliciesandproceduresforstatenewbornscreen-
ing programs (with consideration of a national model);
3. Model minimum standards for state newborn screening
programs (with consideration of national oversight);
4. A model decision matrix for consideration of state new-
born screening program expansion; and
5. Considerationofthevalueofanationalprocessforqual-
ity assurance and oversight.
This report is a response to the HRSA/MCHB request.
I. DEVELOPING A UNIFORM SCREENING PANEL
Asindicatedabove,theAAPTaskForcewasconcernedpar-
ticularly about the lack of uniformity between the state-based
newbornscreeningprogramsandtheneedfor“nationallyrec-
ognized newborn screening system standards and policies.”
There are few existing systems that allow for the assessment of
conditions to determine their appropriateness for newborn
screening. In addition to the original Wilson-Jungner criteria,
somestates(e.g.,Nebraska,Washington)havedevelopedsuch
evaluation criteria and systems and other countries (e.g., Aus-
tralia, Belgium) have developed them as well. However, most
use criteria that are either difficult to quantify or that do not
allowconditionstobecomparativelyrankedadequately.Most
are inadequate with respect to the handling of conditions that
have similar or overlapping disease markers or that may be
detected through the use of multiplex technologies but may
vary in their analytical and clinical features.
METHODS
ACMG convened a group—the Newborn Screening Expert
Group—that included participants with expertise in various
areasofsubspecialtymedicineandprimarycare,healthpolicy,
law, ethics, and public health, as well as consumers, who
worked with a steering committee and several expert work
groups. As an initial step in the process, the expert group de-
veloped a set of guiding principles for its work. The establish-
ment of these principles was followed by the development of
criteriabywhichconditionsweretobeevaluated,andtheiden-
tificationoftheconditionstobeevaluated.Asteeringcommit-
tee oversaw the work of this group. Two work groups were
formedtoprovidemorein-depthanalysisintwospecificareas:
the uniform panel and its criteria, and the diagnosis and
follow-up system.
The expert group used a two-tiered approach to assessing
andrankingconditions.Inthefirsttier,usingthespecificeval-
uationcriteria,conditionswereanalyzedbyrecognizedexperts
and other interested individuals to develop a quantification of
opinion. In the second tier, the quantification data were sub-
jected to an analysis of the evidence base for each specific
screening criterion score. Basic principles developed to guide
the decision-making process were factored with the results of
these two levels of analysis to arrive at a set of core conditions
and the identification of additional clinically significant con-
ditions that could be revealed while establishing the diagnosis
ormadeavailablebythescreeninglaboratoryduetothenature
of the technology being employed.
Establishing principles
The following basic principles were developed as a frame-
work for defining the criteria by which to evaluate conditions
and make recommendations.
1. Universal newborn screening is an essential public health
responsibility that is critical to improve the health out-
come of affected children.
2. Newborn screening policy development should be pri-
marily driven by what is in the best interest of the affected
newborn,withsecondaryconsiderationgiventotheinter-
estsofunaffectednewborns,families,healthprofessionals,
and the public.
3. Newborn screening is more than testing. It is a coordi-
nated and comprehensive system consisting of education,
screening, follow-up, diagnosis, treatment and manage-
ment, and program evaluation.
4. Themedicalhomeandthepublicandprivatecomponents
of the screening programs should be in close communica-
tion to ensure confirmation of test results and the appro-
priate follow-up and care of identified newborns.
5. Recommendations about the appropriateness of condi-
tions for newborn screening should be based on the eval-
uation of scientific evidence and expert opinion.
6. Tobeincludedasaprimarytargetconditioninanewborn
screeningprogram,aconditionshouldmeetthefollowing
minimum criteria:
a. Itcanbeidentifiedataphase(24to48hoursafterbirth)
at which it would not ordinarily be clinically detected;
b. A test with appropriate sensitivity and specificity is
available for it; and
c. There are demonstrated benefits of early detection,
timely intervention and efficacious treatment of the
condition being tested.
ACMG Newborn Screening Expert Group
2S Genetics IN Medicine7. The primary targets of newborn screening should be con-
ditionsthatmeetthecriterialistedinnumber6above.The
newborn screening program also should report any other
result of potential clinical significance.
8. Centralized health information data collection is needed
for longitudinal assessment of disease-specific screening
programs.
9. Total quality management should be applied to newborn
screening programs.
10. Newborn screening specimens are valuable health re-
sources. Every program should have policies in place to
ensure confidential storage and appropriate use of speci-
mens.
11. Public awareness, coupled with professional training and
family education, is a significant program responsibility
that must be part of the complete newborn screening sys-
tem.
Choosing conditions
Theconditionschosenforevaluationwereincludedforone
or more of several reasons:
1. They are included in private, state, or national newborn
screening programs;
2. They are coincidentally revealed by some of the technol-
ogies used in newborn screening;
3. They were identified by members of the expert group as
worthy of consideration;
4. They were identified by disease-specific advocacy orga-
nizations; and/or
5. They were included in the differential diagnosis of a
screening result for another condition.
In the course of collecting information, all conditions were
subject to reconsideration. Eighty-four conditions were cho-
sen for consideration.
Developing evaluation criteria and their comparative values
The uniform panel working group developed the criteria by
which conditions were to be evaluated. These were modified
subsequently by the expert group. Criteria were divided into
three main categories that covered aspects of the condition:
1. The clinical characteristics (e.g., incidence, burden of
disease if not treated, phenotype in the newborn);
2. The analytical characteristics of the screening test (e.g.,
availability, features of the platform); and
3. The diagnosis, treatment and management of the condi-
tion in both acute and chronic forms (this criterion in-
cludestheavailabilityofhealthprofessionalsexperienced
in diagnosis, treatment, and management).
Within each of these categories, several component criteria
weredeveloped(resultinginatotalof19criteria)forassigning
the comparative value or score. The scoring system recognizes
the strengths and limitations of each condition and summa-
rizestheminarankingsystem.Thus,alowscoreinaparticular
area does not necessarily mean that screening for that condi-
tion will never be conducted. In fact, low scores could be rad-
ically overruled by scientific evidence of new advances in test-
ing and treatment, and they should be recognized as
opportunities for targeted research endeavors and subsequent
reconsideration of the condition for inclusion.
The criteria that were developed to differentiate the appro-
priateness of conditions for newborn screening include some
that have a highly objective scientific basis and others that are
associatedwithmoresubjectiveaspects.Totheextentpossible,
the expert group relied on the scientific literature to provide
the information on which its recommendations are based.
However, some criteria have significant subjective aspects that
require the consideration of more than just scientific and ex-
pert opinion. For example, issues of cost were considered but
were not viewed as central in the analyses of the scientific lit-
erature.Costisanexampleofasubjectivecriterionbecauseitis
a contextual concern and can be measured only against the
value of the outcome.
Collecting data
The first tier of the analysis was accomplished through the
development of a data collection instrument containing the
evaluation screening criteria. A survey was conducted to allow
for the input of a wide range of individuals and organizations
withinterestinnewbornscreening.Thedatacollectioninstru-
ment included a methodology not only to collect information
from experts, but also to quantify that expert opinion on fea-
tures of the conditions under consideration for inclusion in a
uniform condition panel.
Beforewidedistribution,thedatacollectioninstrumentwas
pilot tested. Potentially ambiguous language was identified
and clarified, and scores were modestly adjusted to reflect the
evolving priorities of the expert group. After modification, the
data collection instrument was made widely available through
passive efforts (e.g., listservs of interest groups such as Genetic
Alliance, Association of Public Health Laboratories, Associa-
tionofStateandTerritorialHealthOfficials)andactiveefforts
(e.g.,directapproachestoexpertsintheconditionsundereval-
uation and/or to support groups for particular conditions un-
der evaluation). In this way, it was possible to acknowledge
broad views that were of a more subjective nature, such as the
simplicity of the treatment (parents and individuals with the
disorder in question often differed significantly from experts
when scoring on such items as simplicity of treatment). The
results led to a preliminary listing of conditions and their
placement in one of three categories:
1. High scoring;
2. Moderately scoring but part of the differential diagnosis
of a high scoring condition; and
3. Low scoring conditions not appropriate for newborn
screening at this time.
The quantification of responses from at least three recog-
nized experts for each condition were compared with those of
all respondents for that condition and found to be consistent.
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characterized to ensure that they were broadly representative
of the population. Recognizing that not all who respond have
expertise or experience in all aspects of newborn screening for
aspecificcondition,methodswereusedthatalloweddatatobe
aggregated for each criterion for each condition rather than to
use the total score for a condition. A mean score for each cri-
terionforeachconditionwasbasedonlyontheresponsespro-
vided for the criterion. Respondents were allowed to insert a
“U”ifananswerwasunknown.Thesumofthemeanswasused
for the total score assigned to a condition, because the sum of
the means tends to acknowledge dissenting views more clearly
than does the sum of the medians.
It is recognized that this relatively open survey process lim-
ited the views of experts while considering the views of those
less knowledgeable about the individual conditions. However,
analyses provided by scientific experts showed that their views
were in close agreement with those of the majority of respon-
dents.
Establishing and integrating the evidence base
In the second tier of the assessment, the evidence base for
the conditions was established and an algorithm through
which conditions were reassessed was developed. Each con-
dition was considered with regard to the available scientific
evidence, such as systematic reviews of reference lists (in-
cluding MedLine, PubMed and others); books; Internet
searches; professional guidelines; clinical evidence; and
cost/economic evidence and modeling surrounding each of
the criterion. Their categorization was adjusted in accor-
dance with the evidence. The analysis of the evidence base
from the scientific literature included details about the
screening tests, the efficaciousness of treatments, and the
adequacy of the knowledge base of the condition. Disease-
specificfactsheetsweredevelopedtodescribethisevidence.
Atleasttworecognizedexpertsexaminedtheevidenceon
the fact sheet for all criterion scores for the conditions and
assigned the level of evidence for each criterion score, mak-
ingthescoringsystempartofafullerevidencebaseanalysis.
Thus, the evaluation of the evidence for the scores in the
second tier of analysis is part of a broader assessment of the
scientific literature related to the conditions, tests, and
treatments. In addition to validating the evidence gleaned
fromtheliteratureandothersources,theseexpertsassigned
a level of quality to the studies from which the evidence was
drawn. Adjustments based on the evidence were made pri-
marily on the basis of the accuracy of the information.
When significant differences were found between the data
collected through the survey and the evidence base, these
differences are acknowledged and addressed in each of the
fact sheets. Only rarely were adjustments required to align
the literature evidence with the views of the scores of
survey respondents.
RESULTS
In the first tier of assessment, nearly 300 individuals from
the United States and other countries completed the data col-
lection instrument. Many respondents provided information
on multiple conditions, thereby yielding information on nearly
4,000individualdisease-specificresponses.Thecompletedata
are displayed in Table 1 (Scores of All Conditions) and graph-
icallyinFigure1(ScoringbyTestAvailability),wherethesums
of the means are displayed for all conditions. Medium-chain
acyl CoA dehydrogenase (MCAD) deficiency, congenital hy-
pothyroidism (CH) and phenylketonuria (PKU) were the
highest scoring conditions in this evaluation system, followed
by biotinidase deficiency (BIOT), sickle cell anemia (Hb SS)
andcongenitaladrenalhyperplasia(CAH).Anumberofother
conditions that scored in the upper third were also found to
have an efficacious treatment and sufficient knowledge of nat-
ural history to be considered appropriate for newborn screen-
ing. Most conditions in the middle third of scores were also
included in the differential diagnosis of at least one of the
higherscoringconditions.Almostallconditionsinthebottom
third of scores either lacked a screening test that had been
validatedinageneralnewbornpopulationorweredeficientin
meetingseveraloftheassignedevaluationcriteria.Duetolim-
itedinvolvementofinfectiousdiseaseexperts,theexpertgroup
chose to defer decision-making on infectious diseases.
Ascoreof1200onthedatacollectioninstrumentwasfound
toprovidealogicalpointofseparationbetweenagroupofhigh
scoring conditions (1,200–1,799 of a possible 2,100) and an-
other group of low scoring (1,000) conditions. A group of
conditionswithintermediatescores(1,000–1,199)wasidenti-
fied,allofwhichwerepartofthedifferentialdiagnosisofahigh
scoringcorecondition,butwithoutanefficacioustreatmentor
without a well understood natural history. With the use of
expertopinionandthevalidatedevidencebase,eachcondition
thathadbeenpreviouslyassignedtoacategorybasedonquan-
tified scores was reconsidered based on:
1. Thescientificevidenceastotheavailabilityofascreening
test;
2. An efficacious treatment;
3. An adequate understanding of the natural history;
4. Whether the condition was part of the differential diag-
nosis of another condition; and
5. Whether the screening test results related to a clinically
significant condition.
The categories were referred to as: 1) the core panel; 2) sec-
ondary targets (conditions that are part of the differential di-
agnosis of a core panel condition); and 3) not appropriate for
newborn screening (either no newborn screening test is avail-
ableorthereispoorperformancewithregardtomultipleother
evaluation criteria).
DISCUSSION
The basis for decision-making started with whether a
screeningtestisavailable,whichwasthenoverlaidbytheover-
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Scores of all conditions (sorted in descending order of the sum of the means scores)
Condition Code Score (sum of the means) Rank (%ile)
Medium-chain acyl-CoA dehydrogenase deficiency MCAD 1799 1.00
Congenital hypothyroidism CH 1718 0.99
Phenylketonuria PKU 1663 0.98
Neonatal hyperbilirubinemia (Kernicterus) HPRBIL 1584 0.96
Biotinidase deficiency BIOT 1566 0.95
Sickle cell anemia (Hb SS disease) Hb SS 1542 0.94
Congenital adrenal hyperplasia (21-hydroxylase deficiency) CAH 1533 0.93
Isovaleric acidemia IVA 1493 0.89
Very long-chain acyl-CoA dehydrogenase deficiency VLCAD 1493 0.89
Maple syrup (urine) disease MSUD 1493 0.89
Classical galactosemia GALT 1473 0.88
Hb S/-thalassemia Hb S/Th 1455 0.87
Hb S/C disease Hb S/C 1453 0.86
Long-chain L-3-OH acyl-CoA dehydrogenase deficiency LCHAD 1445 0.84
Glutaric acidemia type I GA I 1435 0.83
3-OH 3-CH3 glutaric aciduria HMG 1420 0.82
Trifunctional protein deficiency TFP 1418 0.81
Multiple carboxylase deficiency MCD 1386 0.80
Benign hyperphenylalaninemia H-PHE 1365 0.78
Methylmalonic acidemia (mutase deficiency) MUT 1358 0.77
Homocystinuria (due to CBS deficiency) HCY 1357 0.76
3-Methylcrotonyl-CoA carboxylase deficiency 3MCC 1355 0.75
Hearing loss HEAR 1354 0.73
Methylmalonic acidemia (Cbl A,B) Cbl A,B 1343 0.72
Propionic acidemia PROP 1333 0.71
Carnitine uptake defect CUD 1309 0.69
Galactokinase deficiency GALK 1286 0.69
Glucose-6-phosphate dehydrogenase deficiency G6PD 1286 0.67
-Ketothiolase deficiency BKT 1282 0.66
Citrullinemia CIT 1266 0.65
Argininosuccinic acidemia ASA 1263 0.64
Tyrosinemia type I TYR I 1257 0.63
Short-chain acyl-CoA dehydrogenase deficiency SCAD 1252 0.61
Tyrosinemia type II TYR II 1249 0.60
Glutaric acidemia type II GA2 1224 0.59
Medium/short-chain L-3-OH acyl-CoA dehydrogenase deficiency M/SCHAD 1223 0.58
Cystic fibrosis CF 1200 0.57
Variant hemoglobinopathies (including Hb E) Var Hb 1199 0.55
Human HIV infection HIV 1193 0.54
Defects of biopterin cofactor biosynthesis BIOPT (BS) 1174 0.53
Medium-chain ketoacyl-CoA thiolase deficiency MCKAT 1170 0.52
Carnitine palmitoyltransferase II deficiency CPT II 1169 0.51
(continued)
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Continued
Condition Code Score (sum of the means) Rank (%ile)
Methylmalonic acidemia (Cbl C,D) Cbl C,D 1166 0.49
Argininemia ARG 1151 0.48
Tyrosinemia type III TYR III 1149 0.47
Defects of biopterin cofactor regeneration BIOPT (Reg) 1146 0.46
Malonic acidemia MAL 1143 0.45
Carnitine: acylcarnitine translocase deficiency CACT 1141 0.43
Isobutyryl-CoA dehydrogenase deficiency IBG 1134 0.42
2-Methyl 3-hydroxy butyric aciduria 2M3HBA 1132 0.41
Carnitine palmitoyltransferase I deficiency (liver) CPT IA 1131 0.40
2-Methylbutyryl-CoA dehydrogenase deficiency 2MBG 1124 0.39
Hypermethioninemia MET 1121 0.37
Dienoyl-CoA reductase deficiency DE RED 1119 0.36
Galactose epimerase deficiency GALE 1066 0.35
3-Methylglutaconic aciduria 3MGA 1057 0.34
Severe combined immunodeficiency SCID 1047 0.33
Congenital toxoplasmosis TOXO 1041 0.31
Familial hypercholesterolemia (heterozygote) FHC 1038 0.30
Carnitine palmitoyltransferase I deficiency (muscle) CPT IB 1009 0.29
Citrullinemia type II CIT II 1001 0.28
Ornithine transcarbamylase deficiency OTC 942 0.27
Guanidinoacetate methyltransferase deficiency GAMT 922 0.24
Wilson disease WD 922 0.24
Diabetes mellitus, insulin dependent IDDM 891 0.23
Neuroblastoma NB 864 0.22
Arginine: glycine amidinotransferase deficiency AGAT 861 0.20
Turner syndrome TURNER 847 0.19
Adenosine deaminase deficiency ADA 841 0.18
Carbamylphosphate synthetase deficiency CPS 833 0.17
Alpha 1-antitrypsin deficiency A1AT 819 0.16
Congenital cytomegalovirus infection CMV 779 0.14
Duchenne and Becker muscular dystrophy DMD 776 0.12
Fragile X syndrome FX 776 0.12
Congenital disorder of glycosylation type Ib CDG Ib 766 0.11
Smith-Lemli-Opitz syndrome SLO 759 0.10
Biliary atresia BIL 744 0.08
Hurler-Scheie disease MPS-1H 707 0.07
X-linked adrenoleukodystrophy ALD 705 0.06
Fabry disease FABRY 661 0.05
Creatine transport defect CR TRANS 646 0.04
Lysosomal storage diseases LSD 638 0.02
Pompe disease POMPE 613 0.01
Krabbe disease KRABBE 447 0.00
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lectioninformationtool.Theprocessofquantifyingthisexpert
opinion was then informed by literature review and expert
validation.
In the first tier of analysis, conditions with scores above
1,200 met key criteria and were preliminarily considered ap-
propriate for inclusion in a core newborn screening panel.
Conditionsscoringbelow1,000werenotconsideredappropri-
ate for inclusion in the core newborn screening panel at this
time. As noted previously, the expert group determined that
thelaboratoryshouldreportanyresultcoincidentallyrevealed
in the course of newborn screening that might be clinically
significant. In general, the screening test has been optimized
for the detection of primary target conditions. Optimizing the
technology for a primary target condition does not necessarily
optimize the detection of all possible conditions. These condi-
tions are often revealed through diagnostic testing since they
are part of the differential diagnosis of a core condition as
occurswithMS/MSidentifiedcasesbutmaybeapparentinthe
screening laboratory due to the technologies employed in
screening (e.g., hemoglobinopathies by high pressure liquid
chromatography (HPLC)/isoelectric focusing (IEF)). Hence,
the expert group designated a category of “secondary targets”
to include conditions for which the results should be made
available to health care professionals and/or families by the
screening laboratory or that are determined during the diag-
nosticphaseofthescreeningprogramandprovidedtofamilies
in the course of diagnosis and follow-up. Most conditions
placed in the secondary target category are part of the differ-
ential diagnosis of a condition in the core panel. Inclusion in
the secondary target category allows for the collection of cases
on a national level for further investigation to understand the
disease process, and for the development of treatment modal-
ities. Regardless of whether programs choose to integrate all
such conditions into their broader newborn screening pro-
grams, it will be important for them to have the diagnostic
confirmatory results for all such cases, since they have a direct
impactonthecalculationoffalse-positiveratesofscreeningfor
the core panel conditions.
After conditions were preliminarily categorized based on
their data collection instrument scores, the evidence base, as
reflected in fact sheets developed for each condition, was as-
sessed.Ifaclinicallysignificantconditioninthecorepaneldid
nothavethescientificevidencetosupporttheavailabilityofan
efficacious treatment, it moved to the secondary target cate-
gory. Similarly, if it was determined that an understanding of
the natural history of the condition was insufficient to justify
primary screening, the condition was moved to the secondary
Fig. 1. Scoring by test availability (separates out those conditions that have an acceptable, validated, population-based screening test from those that do not).
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ers of the conditions, the handling of carrier information was
moved into the secondary target category.
The following flow diagram (Fig. 2) demonstrates the deci-
sion-making algorithm. It is important to note that the algo-
rithmpresumes an ongoing review of conditions to determine
their continued or newly identified appropriateness for new-
born screening as new tests and treatment evolve. The data
collection instrument used in this project provides an assess-
ment of only one aspect of a broader decision-making process
Fig. 2. Condition evaluation and decision-making algorithm.
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Anongoinganalysisofthescientificevidencemustbeoverlaid
on the quantified expert opinion.
Clearly, the first decision to screen is based on the availabil-
ity of a sensitive and specific screening test that can be done in
the 24- to 48-hour interval after birth. There are a total of 29
conditions considered appropriate for newborn screening be-
cause they have a screening test, an efficacious treatment, and
there is adequate knowledge of natural history (see Table 2).
The conditions best meeting all of the criteria established by
theexpertgroupareMCAD,CHandPKU.Amongconditions
assignedtothecorepanelarenineorganicacidurias;sixamino
acidurias; five disorders of fatty oxidation; three hemoglobi-
nopathies associated with an Hb S allele; and six other condi-
tions. Twenty-three of the 29 conditions in the core panel are
identified with multiplex technologies such as MS/MS.
On the basis of the evidence, 6 of the 35 conditions placed
initiallyinthecorepanelweremovedintothesecondarytarget
category, which expanded to 25 conditions that are part of the
differential diagnosis of a core panel condition. Knowledge of
these secondary targets (i.e., in a newborn screening test result
or in follow-up) can be clinically important to the family.
In addition to the 54 conditions identified in Table 2, the
expertgroupidentified27otherconditionsthatwerenotcon-
sideredappropriatefornewbornscreening,eitherbecausethey
met few evaluation criteria or because they lacked a screening
test.
Limitations
Conditions with limited evidence reported in the scientific
literature were more difficult to evaluate using the data collec-
tion instrument. For example, some conditions have been re-
ported in 10 or fewer families in the world. Many conditions
were found to occur in multiple forms distinguished by age-
of-onset,severityorotherfeatures.Further,unlessacondition
wasalreadyincludedinnewbornscreeningprograms,apoten-
tial for bias was apparent in the information related to some
criteria. The power of the statistical analyses and the blending
oftwoformsofevaluationalsopresentedlimitations.Thedata
collection process in the first tier of the analysis was limited
alsobythesignificantvariabilityinthenumbersofindividuals
responding for the different conditions. Due to limitations in
the scientific evidence of these rare diseases, there was signifi-
cant reliance on the opinions of experts in the conditions.
There were many conditions that scored close to other condi-
tions and it is unlikely that the statistical power provided in
theseanalyseswassufficienttotrulydiscriminateamongthem
in a ranking system. Nevertheless, groups of scores were as-
sessed and natural separations between groups became appar-
ent.Insuchcircumstances,expertopinionwithreasoningthat
appliedfirstprinciplesofgeneticmedicinetotheevidenceand
tothequalityunderlyingthedatadeterminedtheplacementof
the conditions into particular categories.
II. THE NEWBORN SCREENING SYSTEM:
PROGRAM EVALUATION COST-EFFECTIVENESS
AND FUTURE NEEDS
The newborn screening system
Becausetheappropriatefunctioningofthenewbornscreen-
ingsystemiscriticaltorealizingimprovedoutcomes,thecom-
ponents of a screening program and system were examined by
theexpertgroupduringtheproject(informationwasobtained
from program reports submitted to the National Newborn
Screening and Genetics Resource Center (NNSGRC) and is
based on information available as of October 2003). The goal
of the evaluation was to determine the extent to which States
have addressed the many aspects of the components of this
system and to recommend performance standards to improve
thequalityofthesystem.Theabilitytoproperlyensureappro-
priatediagnosisandmanagementisconsideredtobeprimarily
asystemsresponsibility.Limitationsandsignificantvariability
were identified in components of prenatal education, screen-
Table 2
Newborn screening panel: core panel and secondary targets
MS/MS
Acylcarnitines Amino acids
9 OA 5 FAO 6 AA 3 Hb Pathies 6 Others
COREPANEL
IVA MCAD PKU Hb SS* CH
GA I VLCAD MSUD Hb S/Th* BIOT
HMG LCHAD HCY* Hb S/C* CAH*
MCD TFP CIT GALT
MUT* CUD ASA HEAR
3MCC* TYR I* CF
Cbl A,B*
PROP
BKT
SECONDARYTARGETS
6 OA 8 FAO 8 AA 1 Hb Pathies 2 Others
Cbl C,D* SCAD HYPER-PHE Var Hb* GALK*
MAL GA2 TYR II GALE
IBG M/SCHAD BIOPT (BS)
2M3HBA MCKAT ARG
2MBG CPT II TYR III
3MGA CACT BIOPT (REG)
CPT IA MET
DE RED CIT II
NOTE: Codes are as follows: OA, disorders of organic acid metabolism; FAO,
disorders of fatty acid metabolism; AA, disorders of amino acid metabolism;
Hb Pathies, hemoglobinopathies.
*Identifiesconditionsforwhichspecificdiscussionsofuniqueissuesarefound
in the main report.
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ment. For example:
1. FinancingacrossStateandcountylinesisconstrainedby
State-based Medicaid rules;
2. Service delivery is fragmented on a categorical or disease
basis;
3. Thereisinsufficientsupporttobridgegeographicbar-
riers;
4. It is difficult to identify experienced health care profes-
sionals for complex care (e.g., centers of excellence for
genital reconstructive surgery for CAH; confirmation of
metabolic diagnoses);
5. There is misinterpretation of privacy regulations (e.g.,
the Health Information Portability and Accountability
Act or HIPAA);
6. Thereisunderutilizationandlackofuniformityofinfor-
mation technology;
7. Collaborative management and care is often constrained
by systems of reimbursement for services;
8. State sovereignty sometimes dictates individual ap-
proaches; and
9. There is variability in financing of screening programs.
There are both national and State roles in addressing these
limitations, and states must retain their significant roles and
responsibilities.Theyhaveclearauthoritywithregardtoover-
sightandevaluation,aswellasenforcement.Thereisaneedto
integrate the various systems of health care coverage and pay-
ment through flexible and comprehensive financing of ser-
vices. Service coordination at both State and local levels must
be considered, as well as program integration with the State
Children’s Health Insurance Plan, early intervention pro-
grams, Title V programs, and similar services.
Itisapparent,however,thatallStateprogramscouldbenefit
from a more robust national role in newborn screening. Be-
cause so many of the conditions screened in newborns or un-
der consideration for screening are rare, most States that un-
dertake evaluations of the scientific basis for screening of
conditions must rely on the same relatively small group of
patients identified throughout the world. There is a potential
national role in providing scientific evaluation of conditions
and defining core condition panels. This would allow States to
apply the best science to their own considerations when deter-
mining their role in expanded screening.
Practice guidelines also could be developed at a national
levelbyinterestedorganizations.Theexpertgroupidentifieda
clear gap in the information available and information needed
by primary care professionals to facilitate an immediate re-
sponseintheeventofascreen–positiveinfant.Inresponse,the
expert group has developed an Action (ACT) Sheet for each
core condition and secondary target to facilitate immediate
response on the part of primary care professionals, both with
regardtotheneedforspeedandtheexpectedstepsindiagnosis
and follow-up.
There are also potentially expanded national roles in over-
sight, data collection, program evaluation, and the develop-
ment of educational materials to support newborn screening.
Depending on the overall incidence of particular conditions,
regional collaborative groups such as those funded by HRSA
could:
1. Coordinate access to health care professionals;
2. Serveascoordinatorsandrepositoriesfordatacollection;
3. Provide long-term follow-up capability when resources
and expertise are limited;
4. Facilitate transition (and access) from pediatric to adult
care; and
5. Provide education.
Thedistributionofprimary,secondary,andtertiaryservices
is largely based on the incidence of a condition and the com-
plexityofitsshort-andlong-termdiagnosisandmanagement.
For more common conditions with easier diagnosis and fol-
low-up,thereislikelytobesufficientlocalhealthcareexpertise
for patient care. As incidence decreases and complexity in-
creases—particularly for rare metabolic diseases—services be-
come more difficult to access. Developing resources to ensure
that health care professionals are available locally, regionally,
and nationally will be important to ensuring access to high-
quality services.
Cost-effectiveness analysis
A basic cost-effectiveness assessment project was done to
better inform the decision-making process. This assessment
focusedprimarilyonascientificanalysisofconditionsandthe
featuresthatshouldbeconsideredwhendecidingwhetherthey
should be included in a newborn screening program, since
costs often are the basis on which such decisions are made.
Costs and benefits related to screening for particular condi-
tions or groups of conditions were evaluated after mapping
them over major disease outcomes (e.g., life expectancy, cere-
bral palsy/stroke, seizures, developmental delay, hearing loss,
vision loss). Costs were obtained from the literature and ben-
efits determined from expected outcomes with and without
early treatment or intervention. The results of these analyses
indicate that most newborn screening programs improve out-
comes and reduce overall costs. Further, technologies such as
MS/MS or HPLC save money due to their multiplexing capa-
bilities and low screening false-positive rates. The identifica-
tion of potentially affected individuals at such an early time in
life leads to many years over which the benefits accrue and
aggregate over costs.
CONCLUSIONS
Significant variability in the conditions for which newborns
arescreenedledtothisprojecttoassessthescientificandmed-
ical evidence and the views of the various individuals and in-
terestgroupsrelatedtoconditionsbeingconsidered.Through-
out this undertaking, scientific literature and expert opinion
formed the basis for information collection and assessment.
The expert panel considered a range of information, from the
disease-specific to the full breadth of the newborn screening
ACMG Newborn Screening Expert Group
10S Genetics IN Medicinesystem, in evaluating 84 conditions. There was an effort to
overlaytheevidence,whereavailable,ontopofexpertopinion.
The process of quantifying this expert opinion was informed
by literature review and expert validation. It is important to
acknowledge that there was limited scientific evidence avail-
able on the rare disorders considered by the expert panel. Fur-
ther, because there was limited activity in the area of coordi-
nated data collection and analysis, it seemed unlikely that
robustscientificevidencewouldbeavailableinthenearfuture.
Hence, reliance on experts and their ability to apply first prin-
ciples was required.
Guiding principles for newborn screening and criteria for
evaluating conditions were established. The conditions being
considered were initially assigned through expert analysis to
oneofthreecategories,dependingonhowtheymetthescreen-
ing criteria. The categories were core panel, secondary targets
(conditions that are part of the differential diagnosis of a core
panel condition), and not appropriate for newborn screening
(either no newborn screening test is available or there is poor
performancewithregardtomultipleotherevaluationcriteria).
Each condition was then evaluated to determine the extent
to which the scientific evidence supports the availability of a
test and a treatment, whether the natural history of the condi-
tioniswellunderstood,andwhethertheinformationprovided
bytestingindicatesthepossiblepresenceoftheconditionorof
a carrier state.
The expert panel identified 29 conditions for which screen-
ing should be mandated. An additional 25 conditions were
identifiedbecausetheyarepartofthedifferentialdiagnosisofa
condition in the core panel or are clinically significant and
revealed by the screening technology but lack an efficacious
treatment (as with some identified through MS/MS technol-
ogy) or because there are incidental findings for which there is
potential clinical significance (hemoglobinopathies). The ex-
pert group thought it was important that such findings be
communicated to the health care service community and to
families. In addition, the view that the technologies employed
in newborn screening be maximized is inherent in the recom-
mendation that all clinically significant information discov-
ered through newborn screening be provided to the relevant
health care professionals and/or the family.
The expert group recommends that State newborn screen-
ing programs:
1. Mandate screening for all core panel conditions defined
by this report;
2. Mandatereportingofallsecondarytargetconditionsde-
fined herein and reporting of any abnormal results that
may be associated with clinically significant conditions,
including the definitive identification of carrier status;
3. Maximize the use of multiplex technologies; and
4. Consider that the range of benefits realized by newborn
screening includes treatments that go beyond an infant’s
mortality and morbidity.
The full breadth of the newborn screening system was as-
sessed, including a brief review of its cost-effectiveness. Nu-
merous barriers to implementation of an optimal screening
and follow-up program were identified. Recommended ac-
tions to overcome these barriers include:
1. Establishmentofanationalroleintheon-goingscientific
evaluation of conditions and the technologies by which
they are screened;
2. Standardization of case definitions and reporting proce-
dures;
3. Enhanced oversight of hospital-based screening activi-
ties;
4. Long-term data collection and surveillance; and
5. Consideration of the financial needs of programs.
Recommendations
1. Programs should continue to improve the components
of the newborn screening system beyond the initial
screening, communicate those results, and ensure that
the newborn enters into short-term follow-up.
2. Result reporting procedures should be standardized.
3. Reports of confirmatory results should be obtained.
4. There should be improved oversight (e.g., Joint Com-
mission on Accreditation of Hospital Organizations
(JCAHO) of hospital-based screening activities to im-
prove tracking of screen-positive cases).
5. There should be more uniformity in the language and
definitionoftheperformancestandards(e.g.,repeattest,
second test) monitored and reported by programs.
6. The quality assurance programs involving the diagnostic
and follow-up system should be enhanced.
7. National oversight and authority with appropriate re-
sources should be provided.
8. Systems should be in place for collection of data about
individuals identified as screen-positive in newborn
screening programs.
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